Revenue segments as reported by the company.

Product revenue

Service and other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Goodwill Impairment

Restructuring costs

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bionano Genomics

Bionano Genomics, Inc. is a life sciences instrumentation company, which focuses on the genome analysis space. The firm engages in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline cytogenetics. Its products include Saphyr, Bionano Chips, Bionano Prep Kits, and Bionano Data Solutions. The company was founded by Han Cao in January 2003 and is headquartered in San Diego, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Bionano Genomics reports robust Q1 performance and strategic growth plans

Bionano Genomics demonstrated strong revenue growth and operational progress in Q1 2024.
While facing short-term revenue challenges, the company's strategic initiatives and product advancements position it for long-term success.
Efforts to reduce expenses and expand the customer base underscore Bionano's commitment to sustainable growth.

Bionano Genomics reports Q2 revenue decline, focuses on growth strategies

Bionano Genomics faced revenue decline in Q2 2024, attributed to discontinued services and challenges in China.
Despite operational streamlining efforts, the company aims to drive growth through product advancements and partnerships.
Lowered revenue guidance underscores the need for strategic adjustments to navigate market challenges and optimize performance.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bionano Genomics, Inc. (NASDAQ:BNGO ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Amy Conrad - Investor Relations Erik Holmlin - Chief Executive Officer Chris Stewart - Chief Financial Officer Conference Call Participants Michael Okunewitch - Maxim Group Operator Good day, and welcome to the Bionano Genomics First Quarter 2022 Earnings Conference Call. Today's conference is being recorded.

Bionano Genomics, Inc. (BNGO) CEO Erik Holmlin on Q1 2022 Results - Earnings Call Transcript

- 80% year-over-year revenue growth in Q1 2022

Bionano Genomics Reports First Quarter 2022 Financial Results and Highlights Recent Business Progress

SAN DIEGO, April 28, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO) today announced that it will host a conference call and live webcast on Thursday, May 5th, 2022 at 4:30 p.m. Eastern Time to report financial results for the first quarter 2022 and to highlight recent corporate progress.

Bionano Genomics to Report First Quarter 2022 Financial Results and Host a Conference Call and Webcast on May 5, 2022

Intercept Pharma

Ocugen, Inc.

Select analysts see these small-cap stocks skyrocketing over the next 12 months.

3 Moonshot Stocks With Upside of Up to 709%, According to Wall Street

SAN DIEGO, April 14, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™ software, the leading solution for visualization, interpretation and reporting of genomic data, today announced that the United States Patent and Trademark Office issued two new US Patents, No. 11,291,999 and No. 11,292,713 on April 5, 2022.

Bionano Genomics Announces Issuance of Two U.S. Patents for Novel Methods that Expand Patent Protection for Uses of Nanochannel Arrays in Genome Analysis

BNGO stock has provided positive news from study results lately, but its fundamentals are not great and not a reason to invest in it now. The post The Latest Studies by Bionano Genomics Are Promising, But It's Not a Buy Yet appeared first on InvestorPlace.

The Latest Studies by Bionano Genomics Are Promising, But It's Not a Buy Yet

Version includes a powerful capability for genomic scar analysis for assessments of homologous recombination deficiency (HRD) that provides an efficient, consistent approach for analysis of tumor biomarkers used in pharmacogenomics and other cancer research Version includes a powerful capability for genomic scar analysis for assessments of homologous recombination deficiency (HRD) that provides an efficient, consistent approach for analysis of tumor biomarkers used in pharmacogenomics and other cancer research

Bionano Genomics Announces Release of Version 6.2 of its NxClinical Software with Significant New Capabilities for Cancer Research Applications Including HRD Analysis

The risks may be clear when it comes to Bionano Genomics and BNGO stock. However, investors should see this as a long-term play.

Why Bionano Genomics Stock Is Risky, but a Good Bet

Bionano Genomics, Inc. (BNGO) CEO Erik Holmlin at 2nd Annual Maxim Group Virtual Growth Conference (Transcript)

Ginkgo Bioworks Holdings

Vaxart

These stocks are all about cutting-edge technology.

3 No-Brainer Stocks to Buy Right Now for Less Than $6

SAN DIEGO, March 25, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™ software, the leading solution for visualization, interpretation and reporting of genomic data, today announced the final speaker lineup for its 2022 China Symposium. The Symposium will be held March 26, 2022, and features 9 presentations from leading researchers in China as well as opening messages from Erik Holmlin, PhD, Bionano's president and chief executive officer, and Alka Chaubey, PhD, FACMG, Bionano's chief medical officer.

Bionano Genomics Announces Speaker Lineup for 2022 China Symposium

SAN DIEGO, March 23, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. ( BNGO ), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™ software, the leading solution for visualization, interpretation and reporting of genomic data, announced today that company management will present at the 2022 Maxim Virtual Growth Conference. Erik Holmlin, PhD, Bionano's president and chief executive officer, will participate in a fireside chat on Wednesday, March 30th, 2022 at 12:30 pm PT/3:30 pm ET.

Bionano Genomics to Present at the 2022 Maxim Virtual Growth Conference

Bionano Genomics is working hard to address rare diseases, yet Wall Street doesn't see the value in BNGO stock -- but that could change soon. The post Bionano Genomics Stock Can Regain the Crucial $5 Level appeared first on InvestorPlace.

Bionano Genomics Stock Can Regain the Crucial $5 Level

Clover Health Investments

Color Star Technology

Three strategies for trading penny stocks in 2022 The post How to Invest in Penny Stocks in 2022, 3 Strategies to Use  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

How to Invest in Penny Stocks in 2022, 3 Strategies to Use

If you're willing to endure a slow start, it might be a great stock to own down the line.

Is Bionano Genomics a Buy?

BNGO stock has been a falling knife for the past year. But, with promising fundamentals and good tailwinds, now be the time to take a chance.

Bionano Genomics May Finally Offer a Reward for Your Risk

Key findings from evaluation of 59 Heme Samples and 10 Controls:

Bionano Genomics Announces Publication of Comprehensive Validation of Optical Genome Mapping for Hematologic Neoplasms

Fangdd Network Group

Cenntro Inc

Check these 3 penny stocks out after a recent death cross pattern The post Is the Death Cross a Positive for Penny Stocks? 3 to Watch  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Is the Death Cross a Positive for Penny Stocks? 3 to Watch

Arrival Group

Denison Mines

Here's three penny stocks to watch after a solid day of trading The post 3 Penny Stocks to Watch After the Best Trading Day in Almost 2 Years appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Penny Stocks to Watch After the Best Trading Day in Almost 2 Years

SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClinical™, a leading software solution for visualization, interpretation, and reporting of genomic data, announced today that company management will present virtually at the 32nd Annual Oppenheimer Healthcare Conference. Erik Holmlin, PhD, Bionano's president and chief executive officer, is scheduled to present a corporate overview on Tuesday, March 15th, 2022 at 5:40 am PT/8:40 am ET.

Bionano Genomics to Present at the 32nd Annual Oppenheimer Healthcare Conference

One analyst is modeling significant upside for BNGO stock, and there's financial data to suggest that a 3x move is entirely possible. The post Hold On to Bionano Genomics Stock Until It Reaches $6 at Least appeared first on InvestorPlace.

Hold On to Bionano Genomics Stock Until It Reaches $6 at Least

SAN DIEGO, March 03, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), pioneer of optical genome mapping (OGM) solutions on the Saphyr® system and provider of NxClincial™, a leading software solution for visualization, interpretation and reporting of genomic data, announced today that company management will present virtually at the 42nd Annual Cowen Healthcare Conference. Erik Holmlin, Ph.D., Bionano's chief executive officer, is scheduled to present a corporate overview on Wednesday, March 9th, 2022 at 11:10 am PT/2:10 pm ET.

Bionano Genomics to Present at the 42nd Annual Cowen Healthcare Conference

Bionano Genomics' (BNGO) CEO Erik Holmlin on Q4 2021 Results - Earnings Call Transcript

Bionano Genomics (NASDAQ:BNGO) is a life sciences instrumentation company focused on the genome analysis space. Its products include Saphyr, Bionano Chips, Bionano Prep Kits, and Bionano Data Solutions.

Bionano Genomics Has Attractive Applications But An Unattractive Stock Price

SAN DIEGO, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Tuesday, March 1st, 2022 at 4:30 p.m. Eastern Time to report financial results for the fourth quarter and year end 2021 and to highlight recent corporate progress.

News for Bionano Genomics Stock (BNGO)